The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Antisense and RNAi Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
The global Antisense and RNAi Therapeutics market size is expected to reach US$ 1881.9 million by 2029, growing at a CAGR of 5.5% from 2023 to 2029. The market is mainly driven by the significant applications of Antisense and RNAi Therapeutics in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Antisense and RNAi Therapeutics market. RNA Interference, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antisense RNA segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Antisense and RNAi Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Antisense and RNAi Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Antisense and RNAi Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Antisense and RNAi Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Antisense and RNAi Therapeutics covered in this report include Tekmira Pharmaceuticals, Arbutus Biopharma, Alnylam Pharmaceuticals, Antisense Therapeutics, Silence Therapeutics, Isis Pharmaceuticals, Sirnaomics, Santaris and Roche, etc.
The global Antisense and RNAi Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Tekmira Pharmaceuticals
Arbutus Biopharma
Alnylam Pharmaceuticals
Antisense Therapeutics
Silence Therapeutics
Isis Pharmaceuticals
Sirnaomics
Santaris
Roche
Global Antisense and RNAi Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antisense and RNAi Therapeutics market, Segment by Type:
RNA Interference
Antisense RNA
Global Antisense and RNAi Therapeutics market, by Application
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Antisense and RNAi Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Antisense and RNAi Therapeutics market size is expected to reach US$ 1881.9 million by 2029, growing at a CAGR of 5.5% from 2023 to 2029. The market is mainly driven by the significant applications of Antisense and RNAi Therapeutics in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Antisense and RNAi Therapeutics market. RNA Interference, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antisense RNA segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Antisense and RNAi Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Antisense and RNAi Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Antisense and RNAi Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Antisense and RNAi Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Antisense and RNAi Therapeutics covered in this report include Tekmira Pharmaceuticals, Arbutus Biopharma, Alnylam Pharmaceuticals, Antisense Therapeutics, Silence Therapeutics, Isis Pharmaceuticals, Sirnaomics, Santaris and Roche, etc.
The global Antisense and RNAi Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Tekmira Pharmaceuticals
Arbutus Biopharma
Alnylam Pharmaceuticals
Antisense Therapeutics
Silence Therapeutics
Isis Pharmaceuticals
Sirnaomics
Santaris
Roche
Global Antisense and RNAi Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antisense and RNAi Therapeutics market, Segment by Type:
RNA Interference
Antisense RNA
Global Antisense and RNAi Therapeutics market, by Application
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Antisense and RNAi Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Antisense and RNAi Therapeutics
1.1 Antisense and RNAi Therapeutics Market Overview
1.1.1 Antisense and RNAi Therapeutics Product Scope
1.1.2 Antisense and RNAi Therapeutics Market Status and Outlook
1.2 Global Antisense and RNAi Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Antisense and RNAi Therapeutics Market Size by Region (2018-2029)
1.4 Global Antisense and RNAi Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Antisense and RNAi Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Antisense and RNAi Therapeutics Market Size (2018-2029)
1.6.1 North America Antisense and RNAi Therapeutics Market Size (2018-2029)
1.6.2 Europe Antisense and RNAi Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Antisense and RNAi Therapeutics Market Size (2018-2029)
1.6.4 Latin America Antisense and RNAi Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Antisense and RNAi Therapeutics Market Size (2018-2029)
2 Antisense and RNAi Therapeutics Market by Type
2.1 Introduction
2.1.1 RNA Interference
2.1.2 Antisense RNA
2.2 Global Antisense and RNAi Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Antisense and RNAi Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Antisense and RNAi Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Antisense and RNAi Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Antisense and RNAi Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Antisense and RNAi Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Antisense and RNAi Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Antisense and RNAi Therapeutics Revenue Breakdown by Type (2018-2029)
3 Antisense and RNAi Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.2 Global Antisense and RNAi Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Antisense and RNAi Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Antisense and RNAi Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Antisense and RNAi Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Antisense and RNAi Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Antisense and RNAi Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Antisense and RNAi Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Antisense and RNAi Therapeutics Revenue Breakdown by Application (2018-2029)
4 Antisense and RNAi Therapeutics Competition Analysis by Players
4.1 Global Antisense and RNAi Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antisense and RNAi Therapeutics as of 2022)
4.3 Date of Key Players Enter into Antisense and RNAi Therapeutics Market
4.4 Global Top Players Antisense and RNAi Therapeutics Headquarters and Area Served
4.5 Key Players Antisense and RNAi Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Antisense and RNAi Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Tekmira Pharmaceuticals
5.1.1 Tekmira Pharmaceuticals Profile
5.1.2 Tekmira Pharmaceuticals Main Business
5.1.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Products, Services and Solutions
5.1.4 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Tekmira Pharmaceuticals Recent Developments
5.2 Arbutus Biopharma
5.2.1 Arbutus Biopharma Profile
5.2.2 Arbutus Biopharma Main Business
5.2.3 Arbutus Biopharma Antisense and RNAi Therapeutics Products, Services and Solutions
5.2.4 Arbutus Biopharma Antisense and RNAi Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Arbutus Biopharma Recent Developments
5.3 Alnylam Pharmaceuticals
5.3.1 Alnylam Pharmaceuticals Profile
5.3.2 Alnylam Pharmaceuticals Main Business
5.3.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Products, Services and Solutions
5.3.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Antisense Therapeutics Recent Developments
5.4 Antisense Therapeutics
5.4.1 Antisense Therapeutics Profile
5.4.2 Antisense Therapeutics Main Business
5.4.3 Antisense Therapeutics Antisense and RNAi Therapeutics Products, Services and Solutions
5.4.4 Antisense Therapeutics Antisense and RNAi Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Antisense Therapeutics Recent Developments
5.5 Silence Therapeutics
5.5.1 Silence Therapeutics Profile
5.5.2 Silence Therapeutics Main Business
5.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Products, Services and Solutions
5.5.4 Silence Therapeutics Antisense and RNAi Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Silence Therapeutics Recent Developments
5.6 Isis Pharmaceuticals
5.6.1 Isis Pharmaceuticals Profile
5.6.2 Isis Pharmaceuticals Main Business
5.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Products, Services and Solutions
5.6.4 Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Isis Pharmaceuticals Recent Developments
5.7 Sirnaomics
5.7.1 Sirnaomics Profile
5.7.2 Sirnaomics Main Business
5.7.3 Sirnaomics Antisense and RNAi Therapeutics Products, Services and Solutions
5.7.4 Sirnaomics Antisense and RNAi Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Sirnaomics Recent Developments
5.8 Santaris
5.8.1 Santaris Profile
5.8.2 Santaris Main Business
5.8.3 Santaris Antisense and RNAi Therapeutics Products, Services and Solutions
5.8.4 Santaris Antisense and RNAi Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Santaris Recent Developments
5.9 Roche
5.9.1 Roche Profile
5.9.2 Roche Main Business
5.9.3 Roche Antisense and RNAi Therapeutics Products, Services and Solutions
5.9.4 Roche Antisense and RNAi Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Roche Recent Developments
6 North America
6.1 North America Antisense and RNAi Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Antisense and RNAi Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Antisense and RNAi Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Antisense and RNAi Therapeutics Market Dynamics
11.1 Antisense and RNAi Therapeutics Industry Trends
11.2 Antisense and RNAi Therapeutics Market Drivers
11.3 Antisense and RNAi Therapeutics Market Challenges
11.4 Antisense and RNAi Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
